Carisma Therapeutics, Inc.CARMNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+108.4%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+108.4%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
39.3x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 557.51% |
| Q2 2025 | -5.48% |
| Q1 2025 | 47.46% |
| Q4 2024 | -38.84% |
| Q3 2024 | -13.80% |
| Q2 2024 | 41.18% |
| Q1 2024 | 9.45% |
| Q4 2023 | 2.08% |
| Q3 2023 | -7.68% |
| Q2 2023 | 19.34% |
| Q1 2023 | -47.21% |
| Q4 2022 | 8.66% |
| Q3 2022 | -23.43% |
| Q2 2022 | -31.26% |
| Q1 2022 | -226.48% |
| Q4 2021 | 187.30% |
| Q3 2021 | -12.64% |
| Q2 2021 | 83.62% |
| Q1 2021 | -269.86% |
| Q4 2020 | 33.61% |
| Q3 2020 | 14.18% |
| Q2 2020 | -163.38% |
| Q1 2020 | 223.88% |
| Q4 2019 | -155.51% |
| Q3 2019 | 75.83% |
| Q2 2019 | -738.50% |
| Q1 2019 | 4.10% |
| Q4 2018 | 51.79% |
| Q3 2018 | -56.45% |
| Q2 2018 | -126.04% |
| Q1 2018 | 39.47% |
| Q4 2017 | 28.09% |
| Q3 2017 | -24.45% |
| Q2 2017 | -20.71% |
| Q1 2017 | -71.65% |
| Q4 2016 | -118.12% |
| Q3 2016 | 400.22% |
| Q2 2016 | 17.01% |
| Q1 2016 | 27.26% |
| Q4 2015 | -6.46% |